Phase III
Two Phase III studies of lumasiran showed a significant reduction in urinary oxalate excretion in patients of all ages with PH1. Know more about it here.
Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. More than one-third of this cohort includes minority participants.
Shares of AstraZeneca dropped slightly Wednesday afternoon following reports that a patient participating in the Brazilian arm of the company’s global Phase III study has died.
The U.S. arm of the trial has been paused for more than a month while the U.S. Food and Drug Administration investigates a serious illness that occurred in a patient who received the experimental treatment.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.
New data presented at the IASLC 2020 North America Conference on Lung Cancer shows a combination of Keytruda with other medications has a positive impact on non-small cell lung cancer.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Pfizer will not seek Emergency Use Authorization for its COVID-19 vaccine until the end of November even if the readout from a Phase III study expected later this month is positive.
Putin touts efficacy and safety of new vaccine without the data to back him up.
PRESS RELEASES